Novavax reported that phase 3 testing of its COVID-19 vaccine yielded an overall 90% efficacy and 100% protection against moderate and severe illness caused by the Covid-19 virus.
The study summoned 29,960 participants in 119 locations in the United States and Mexico, with special representation from the demographic groups and communities most affected by the coronavirus.
Although several subsequent phases of testing are still pending, the company said it plans to request authorization for use in the fourth quarter of the year and that it could produce 150 million doses per month by that time.
The Novavax press release also indicated that the vaccine was 93.2% effective against the virus variants of greatest concern.
If the implementation of this vaccine is approved in the US, it would be the fourth after the authorization of use granted to Pfizer, Moderna and Johnson & Johnson.